



# Vyndaqel in UAE

*The MoHAP named-patient coordination pathway — indicative 2026*

CARDIOLOGY · ATTR CARDIOMYOPATHY

## The clinical situation

Vyndaqel (tafamidis meglumine 80 mg, or Vyndamax 61 mg) is an FDA-approved oral transthyretin stabiliser indicated for transthyretin amyloid cardiomyopathy (ATTR-CM), dosed once daily. Manufactured by Pfizer. Capsules are stored ambient. Baseline echocardiogram, cardiac biomarkers, and TTR genetic testing (wild-type vs. variant) are confirmed before initiation, with periodic cardiac monitoring during treatment.

### The pathway, 5 steps

- 1 Consultation & diagnostic confirmation.** Treating cardiologist confirms ATTR-CM by nuclear scintigraphy or biopsy; wild-type vs. variant TTR distinguished by genetic testing.
- 2 Treating centre & prescription confirmed.** A UAE tertiary cardiology centre (Abu Dhabi or Dubai) issues the prescription and commits to cardiac monitoring.
- 3 MoHAP named-patient application.** Clinical rationale, imaging, genetic report, prescription, and product details are filed for MoHAP review.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient courier shipment booked.
- 5 Dispensing & monitoring.** Capsules delivered to the patient or treating centre; echocardiographic and biomarker monitoring per label; refills coordinated on a 30-day cycle.

### Indicative economics

**Reference US cash-pay range:** USD 18,000–20,000 per 30-day supply drug-only. Ambient logistics, MoHAP documentation, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-fill timing

**7–14 days** from a complete MoHAP application to first-fill delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** MoHAP named-patient package with imaging and genetic confirmation. **Logistics.** Ambient, tracked courier shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating cardiologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Vyndaqel × UAE first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/vyndaqel-uae.html](https://reservemed.com/access-guides/vyndaqel-uae.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team